Kyu Kwang Kim

Summary

Affiliation: Women and Infants' Hospital
Country: USA

Publications

  1. pmc Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of RI, Alpert Medical School of Brown University, Providence, RI 02905, USA
    BMC Cancer 10:72. 2010
  2. pmc Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, RI 02905, USA
    BMC Cancer 12:147. 2012
  3. pmc Integrated genomics of ovarian xenograft tumor progression and chemotherapy response
    Ashley Stuckey
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants7 Hospital, Alpert Medical School of Brown University, Providence, RI 02905, USA
    BMC Cancer 11:308. 2011
  4. doi Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of Rhode Island, Providence, RI 02905, USA
    Int J Oncol 40:227-35. 2012
  5. pmc Organometallic iron(III)-salophene exerts cytotoxic properties in neuroblastoma cells via MAPK activation and ROS generation
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, Rhode Island, United States of America
    PLoS ONE 6:e19049. 2011
  6. doi Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, RI, USA
    Gynecol Oncol 122:183-9. 2011
  7. pmc Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells
    Thilo S Lange
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of RI, Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America
    PLoS ONE 3:e2303. 2008
  8. pmc A novel indole ethyl isothiocyanate (7Me-IEITC) with anti-proliferative and pro-apoptotic effects on platinum-resistant human ovarian cancer cells
    Rakesh K Singh
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gysnecology, Women and Infants Hospital, Brown University, Providence, RI 02905, USA
    Gynecol Oncol 109:240-9. 2008
  9. pmc Effect of a vitamin D(3) derivative (B3CD) with postulated anti-cancer activity in an ovarian cancer animal model
    Thilo S Lange
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of RI, Warren Alpert Medical School of Brown University, Providence, RI 02905, USA
    Invest New Drugs 28:543-53. 2010
  10. ncbi Oral RKS262 reduces tumor burden in a neuroblastoma xenograft animal model and mediates cytotoxicity through SAPK/JNK and ROS activation in vitro
    Rakesh K Singh
    Women and Infants Hospital, Department of Obstetrics and Gynecology, Alpert Medical School of Brown University, Providence, RI, USA
    Cancer Biol Ther 11:1036-45. 2011

Collaborators

Detail Information

Publications15

  1. pmc Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of RI, Alpert Medical School of Brown University, Providence, RI 02905, USA
    BMC Cancer 10:72. 2010
    ..In present study, we evaluated the effects of various lipophilic aroylhydrazone chelators (AHC), including novel compound HNTMB, on various ovarian cancer cell lines (SKOV-3, OVCAR-3, NUTU-19)...
  2. pmc Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, RI 02905, USA
    BMC Cancer 12:147. 2012
    ....
  3. pmc Integrated genomics of ovarian xenograft tumor progression and chemotherapy response
    Ashley Stuckey
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants7 Hospital, Alpert Medical School of Brown University, Providence, RI 02905, USA
    BMC Cancer 11:308. 2011
    ..In this study we identify genes and gene networks important for the efficacy of a pre-clinical anti-tumor therapeutic, MT19c...
  4. doi Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of Rhode Island, Providence, RI 02905, USA
    Int J Oncol 40:227-35. 2012
    ....
  5. pmc Organometallic iron(III)-salophene exerts cytotoxic properties in neuroblastoma cells via MAPK activation and ROS generation
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, Rhode Island, United States of America
    PLoS ONE 6:e19049. 2011
    ..We report here that Fe-SP is a potent growth-suppressing and cytotoxic agent for in vitro NB cell lines and, due to its high tolerance in previous animal toxicity studies, a potential therapeutic drug to treat NB tumors in vivo...
  6. doi Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, RI, USA
    Gynecol Oncol 122:183-9. 2011
    ..This study tests the hypothesis that TM can modulate antioxidants in tumor cells and render doxorubicin resistant tumor cells sensitive to doxorubicin...
  7. pmc Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells
    Thilo S Lange
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of RI, Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America
    PLoS ONE 3:e2303. 2008
    ....
  8. pmc A novel indole ethyl isothiocyanate (7Me-IEITC) with anti-proliferative and pro-apoptotic effects on platinum-resistant human ovarian cancer cells
    Rakesh K Singh
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gysnecology, Women and Infants Hospital, Brown University, Providence, RI 02905, USA
    Gynecol Oncol 109:240-9. 2008
    ..Key mechanisms of the cellular response in vitro were studied and suggest a potential of 7Me-IEITC as a therapeutic drug...
  9. pmc Effect of a vitamin D(3) derivative (B3CD) with postulated anti-cancer activity in an ovarian cancer animal model
    Thilo S Lange
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of RI, Warren Alpert Medical School of Brown University, Providence, RI 02905, USA
    Invest New Drugs 28:543-53. 2010
    ..B3CD possesses anti-ovarian cancer properties in vitro and in vivo. We propose the further development of non-calcemic bromoacetoxy derivatives of vitamin D(3) as potential anti-cancer therapeutics...
  10. ncbi Oral RKS262 reduces tumor burden in a neuroblastoma xenograft animal model and mediates cytotoxicity through SAPK/JNK and ROS activation in vitro
    Rakesh K Singh
    Women and Infants Hospital, Department of Obstetrics and Gynecology, Alpert Medical School of Brown University, Providence, RI, USA
    Cancer Biol Ther 11:1036-45. 2011
    ....
  11. doi Description of the cytotoxic effect of a novel drug Abietyl-Isothiocyanate on endometrial cancer cell lines
    Timothy C Horan
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, 101 Dudley Street, Providence, RI 02905, USA
    Invest New Drugs 30:1460-70. 2012
    ..Key mechanisms during cell death are predominantly correlated to excess generation of ROS. We suggest the further development of ABITC as a potential therapeutic by studying the drug efficacy in EC in-vivo models...
  12. doi A coumarin derivative (RKS262) inhibits cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells
    Rakesh K Singh
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of RI, The Warren Alpert Medical School of Brown University, 101 Dudley Street, Providence, RI 02905, USA
    Invest New Drugs 29:63-72. 2011
    ....
  13. doi Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines
    Laurent Brard
    Department of Obstetrics and Gynecology, Alpert Medical School, Brown University, Providence, RI 02905, USA
    Gynecol Oncol 123:370-8. 2011
    ..This study was designed to evaluate a novel non-hypercalcemic vitamin-D derivative (MT19c) and its anticancer effects in cultured ovarian cancer cell model...
  14. pmc Apoptotic and chemotherapeutic properties of iron (III)-salophene in an ovarian cancer animal model
    Thilo S Lange
    Division of Biology and Medicine, Brown University, Providence, RI, USA
    Drug Des Devel Ther 3:17-26. 2009
    ..An ovarian cancer animal model showed that the chemotherapeutic relevant dose of Fe-SP in rats is 0.5-1 mg/kg body weight. The present report suggests that Fe-SP is a potential therapeutic drug to treat ovarian cancer...
  15. pmc Anti-proliferative and pro-apoptotic properties of 3-bromoacetoxy calcidiol in high-risk neuroblastoma
    Thilo S Lange
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of RI, Providence, RI 02905, USA
    Chem Biol Drug Des 70:302-10. 2007
    ..These results suggest that B3CD could be developed as a treatment for NB...